Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab/Vibostolimab (MK-7684A) + Chemotherapy vs Pembrolizumab + Chemotherapy in First-Line Metastatic NSCLC
NCT05226598Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of vibostolimab + pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Mar 2022; status: terminated.
02
Drugs
vibostolimab + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05226598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226598.